



Clene to Present at Upcoming October Conferences

October 9, 2024

SALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in October.

2024 Maxim Healthcare Virtual Summit

Date: October 15-17, 2024

Location: Virtual

Presentation: October 15, 2024, at 2:30 p.m. E.T.

Format: Fireside Presentation and 1x1 meetings

Attendance: Sign up to become an [M-Vest member](#)

The ThinkEquity Conference 2024

Dates: October 30, 2024

Location: New York, New York, Mandarin Oriental Hotel

Presentation: October 30, 2024, at 3:30 p.m. E.T.

Format: Presentation and 1x1 meetings

Webcast Link: <https://wsw.com/webcast/tep25/clnn/1673136>

About Clene

Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on [X \(formerly Twitter\)](#) and [LinkedIn](#).

Contacts:

Media Contact

Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC

ignacio.guerrero-ros@russopartnersllc.com

David.schull@russopartnersllc.com

(858) 717-2310

Investor Contact

Kevin Gardner

LifeSci Advisors

kgardner@lifesciadvisors.com

617-283-2856